HIV Subtypes and Drug-resistance-associated Mutations in US Blood Donors, 2015-2020
Brian Custer,Eda Altan,Leilani Montalvo,Alison Coyne,Eduard Grebe,Xutao Deng,Mars Stone,Eric Delwart,Sonia Bakkour,Benyam Hailu,Rita Reik,Debra Kessler,Susan L Stramer,Michael P Busch,Transfusion Transmissible Infections Monitoring System (TTIMS) Program,E Notari,S Stramer,R Dodd,G Conti,R Fayed,D Nelson,R Townsend,G Foster,J Haynes,E Crawford,E Huseynova,D Krysztof,D Burke,M Lanteri,V Green,S Cyrus,P Williamson,D Kessler,J Gorlin,L Milan-Benson,C DelValle,P Chien,T Brown,R Reik,C Shea,M Lopez,K Richards,T Foster,J Brodsky,M Barr,T Rains,B Custer,R Bruhn,E Grebe,M Busch,M Stone,C Di Germanio,D Hindes,Z Kaidarova,K Zurita,A Tadena,L Montalvo,A Dayana,S Hughes,M Townsend,M Bravo,J Vannoy,S Fallon,S Anderson,B Whitaker,H Yang,A Belov,A Eder,B Hailu,S Zou,J Berger,Susan Stramer,Phillip Williamson,Steven A Anderson
DOI: https://doi.org/10.1093/ofid/ofae343
2024-06-17
Abstract:Background: Monitoring genotypes of HIV infections in blood donors may provide insights into infection trends in the general population. Methods: HIV RNA was extracted from plasma samples of blood donors confirmed as HIV positive by blood screening nucleic acid and antibody tests. HIV genome target regions were amplified using nested real time-polymerase chain reaction followed by next-generation sequencing. Sequences were compared to those in the Los Alamos National Laboratory (LANL) database. Sequences were also assessed for drug resistance mutations (DRM) using the Stanford HIV DRM Database. Results: From available HIV-positive donations collected between 1 September 2015 and 31 December 2020, 563 of 743 (75.8%) were successfully sequenced; 4 were subtype A, 543 subtype B, 5 subtype C, 1 subtype G, 5 circulating recombinant forms (CRF), and 2 were subtype B and D recombinants. Overall, no significant differences between blood donor and available LANL genotypes were found, and the genotypes of newly acquired versus prevalent HIV infections in donors were similar. The proportion of non-B subtypes and CRF remained a small fraction, with no other subtype or CRF representing more than 1% of the total. DRM were identified in 122 (21.6%) samples with protease inhibitor, nucleoside reverse transcriptase inhibitor and non-nucleoside reverse transcriptase inhibitor DRMs identified in 4.9%, 4.6% and 14.0% of samples, respectively. Conclusions: HIV genetic diversity and DRM in blood donors appear representative of circulating HIV infections in the US general population and may provide more information on infection diversity than sequences reported to LANL, particularly for recently transmitted infections.